Investors
OMX Stockholm
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Upcoming events
Jefferies Global Healthcare Conference in London
DNB Nordic Healthcare Conference 2025 Oslo
Year-End Report January-December 2025
Press releases
Our latest press releases
13/11/2025
12/11/2025
05/11/2025
Regulatory press release
31/10/2025
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
Upcoming Key Catalysts
Desensitization: Transplantation and Gene Therapy
Kidney Transplant: BLA filing with the FDA, requesting priority review
Phase 2 Top Line Data Readout: global trial in Crigler Najjar with Genethon (GNT-018-IDES)
Autoimmune Disease
Phase 3 Top Line Data Readout: global trial in anti-GBM (GOOD-IDES-02)
Phase 2 Data Publication: single arm trial in GBS (15-HMedIdeS-09)
